Kidney cancer: Neoadjuvant targeted therapies in renal cell carcinoma

Nature Reviews Urology

Volumn 7, Issue 2, 2010, Pages 63-64

  Ficarra, Vincenzo ^a   Novara, Giacomo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANGIOGENESIS; CANCER RECURRENCE; CANCER SURGERY; DRUG TARGETING; GENETIC TRANSDUCTION; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; SHORT SURVEY; ADJUVANT THERAPY; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEM; KIDNEY NEOPLASMS; NEPHRECTOMY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEPHRECTOMY;

EID: 77049096538     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.2     Document Type: Short Survey

References (10)

1. Thomas, A. A. et al. surgical resection of renal cell carcinoma after targeted therapy. J. Urol. 182, 881-886 (2009).
2. Flanigan, R. C. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
3. Motzer, R. J. et al. sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
4. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
5. escudier, B. et al. sorafenib in advanced clearcell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
6. Amin, C. et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72, 864-868 (2008).
7. Bex, A. et al. neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J. Urol. 27, 533-539 (2009).
8. Karakiewicz, P. i. et al. neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol. 53, 845-848 (2008).
9. shuch, B. et al. neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 102, 692-696 (2008).
10. Margulis, v. et al. surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180, 94-98 (2008).